Removing excess sFlt-1 from mothers' blood to help preeclampsia
Official title: New Therapeutic Strategy Against Preeclampsia : Angiogenic Switch to Physiological State by Extracorporeal Removal of sFlt-1 and Release of PlGF
Run by Assistance Publique - Hôpitaux de Paris · NCT06464159 · Data updated 2026-11-12
This project will collect blood from pregnant people with and without preeclampsia to see which patients might benefit from removing excess sFlt-1 from the blood.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | Women only |
| Enrollment | 100 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | February 10, 2026 |
| Main results expected | February 2028 |
| Study ends | November 2028 |
| Registry record updated | May 6, 2026 |
| Trial ID | NCT06464159 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are pregnant people aged 18–50 with a singleton pregnancy between 20 and 41 weeks who have confirmed preeclampsia or are uncomplicated controls and can attend Port-Royal Maternity for blood collection.
✕Probably not a fit
People with multiple pregnancies, active HIV/HBV/HCV infection, under 18, without social security coverage, or whose preeclampsia is not driven by sFlt-1 excess are unlikely to benefit from this specific approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, non-interventional biobank collecting maternal plasma and serum from 50 pregnancies complicated by preeclampsia and 50 normal pregnancies at Port-Royal Maternity (Cochin APHP). Samples will be taken across defined gestational-age windows and analyzed for circulating angiogenic and anti-angiogenic factors (free and total forms), with most assays performed at the hormonology laboratory in Cochin hospital. The molecular profiles will be used to characterize angiogenic balance heterogeneity in preeclampsia and to optimize and validate extracorporeal sFlt-1 purification techniques. The goal is to identify which angiogenic profiles best correspond to a potential indication for apheresis.
Why it matters
Potential benefit: If successful, this work could identify patients likely to benefit from extracorporeal sFlt-1 removal and help delay delivery or reduce maternal symptoms, improving outcomes for mother and baby.
How similar studies have gone: Small pilot studies and case reports of extracorporeal sFlt-1 removal have shown promising physiological and clinical signals, but larger randomized trials are still lacking.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age from 18 to 50 years old * Singleton pregnancies between 20 and 41 weeks of gestation * Preeclampsia / normal pregnancy Exclusion Criteria: * Age \< 18 years old * Infectious disease: HIV, HBV or HCV * Multiple pregnancies * refusal to participate in the protocol * Lack of social security cover
Where it's running
-
Maternité Port-Royal
Paris, France Recruiting
Study contacts
- Principal investigator: Vassilis TSASARIS, MD, PhD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Vassilis TSASARIS, MD, PhD
- Email: vassilis.tsasaris@aphp.fr
- Phone: +33 158413871
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting Adverse Pregnancy Outcomes in Uganda through Partnerships and Innovation
This study tests whether everyday health data, ultrasound, and blood samples from first-time pregnant women in Uganda can help predict problems like preeclampsia, fetal growth restriction, and preterm birth.
-
Internal jugular vein collapsibility to gauge volume status in preeclampsia vs. normal pregnancy
This study tests whether ultrasound of the internal jugular vein can show differences in fluid status between preeclamptic pregnant people and those with normal blood pressure during planned cesarean delivery.
-
Higher vs lower daily aspirin in high-risk pregnant people
This study tests whether taking 150 mg of aspirin daily is more effective than 75 mg daily in preventing preeclampsia among pregnant people at high risk.
-
Community health worker support to lower blood pressure after pregnancy with high blood pressure
Postpartum patients with high blood pressure after pregnancy will try a program where a trained community health worker helps them monitor blood pressure and manage care for 6 months to see if it lowers blood pressure compared with usual care.
-
Role of Progesterone Membrane Receptors in Preeclampsia
This study looks at whether the levels of progesterone membrane receptors in the placenta differ between women with preeclampsia and healthy pregnant women to understand the condition better.
-
Endothelial Biomarkers in Pregnancy: Endothelial Extracellular Vesicles and Hypertensive Disorders
This study tests whether endothelial extracellular vesicles in the blood differ between normotensive pregnant women and those with hypertensive disorders of pregnancy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.